Development and Validation of a Multiparameterized Artificial Neural Network for Prostate Cancer Risk Prediction and Stratification.

PURPOSE To develop and validate a multiparameterized artificial neural network (ANN) on the basis of personal health information for prostate cancer risk prediction and stratification. METHODS The 1997 to 2015 National Health Interview Survey adult survey data were used to train and validate a multiparameterized ANN, with parameters including age, body mass index, diabetes status, smoking status, emphysema, asthma, race, ethnicity, hypertension, heart disease, exercise habits, and history of stroke. We developed a training set of patients ≥ 45 years of age with a first primary prostate cancer diagnosed within 4 years of the survey. After training, the sensitivity and specificity were obtained as functions of the cutoff values of the continuous output of the ANN. We also evaluated the ANN with the 2016 data set for cancer risk stratification. RESULTS We identified 1,672 patients with prostate cancer and 100,033 respondents without cancer in the 1997 to 2015 data sets. The training set had a sensitivity of 21.5% (95% CI, 19.2% to 23.9%), specificity of 91% (95% CI, 90.8% to 91.2%), area under the curve of 0.73 (95% CI, 0.71 to 0.75), and positive predictive value of 28.5% (95% CI, 25.5% to 31.5%). The validation set had a sensitivity of 23.2% (95% CI, 19.5% to 26.9%), specificity of 89.4% (95% CI, 89% to 89.7%), area under the curve of 0.72 (95% CI, 0.70 to 0.75), and positive predictive value of 26.5% (95% CI, 22.4% to 30.6%). For the 2016 data set, the ANN classified all 13,031 patients into low-, medium-, and high-risk subgroups and identified 5% of the cancer population as high risk. CONCLUSION A multiparameterized ANN that is based on personal health information could be used for prostate cancer risk prediction with high specificity and low sensitivity. The ANN can further stratify the population into three subgroups that may be helpful in refining prescreening estimates of cancer risk.

[1]  Andrew J. Vickers,et al.  NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  Jun Deng,et al.  Predicting non-melanoma skin cancer via a multi-parameterized artificial neural network , 2018, Scientific Reports.

[3]  K. Bibbins-Domingo,et al.  The US Preventive Services Task Force 2017 Draft Recommendation Statement on Screening for Prostate Cancer: An Invitation to Review and Comment. , 2017, JAMA.

[4]  B. Henderson,et al.  Association of diabetes with prostate cancer risk in the multiethnic cohort. , 2009, American journal of epidemiology.

[5]  P. Lambin,et al.  Machine Learning methods for Quantitative Radiomic Biomarkers , 2015, Scientific Reports.

[6]  R. Severson,et al.  Body mass and prostatic cancer: a prospective study. , 1988, BMJ.

[7]  A. Pollack,et al.  Ethnic heterogeneity and prostate cancer mortality in Hispanic/Latino men: a population-based study , 2017, Oncotarget.

[8]  I. Kohane,et al.  Development of phenotype algorithms using electronic medical records and incorporating natural language processing , 2015, BMJ : British Medical Journal.

[9]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[10]  Xiangyi Zheng,et al.  Hypertension and risk of prostate cancer: a systematic review and meta-analysis , 2016, Scientific Reports.

[11]  G. Matheson,et al.  Exercise and Prostate Cancer , 2004, Sports medicine.

[12]  P. Sasieni,et al.  Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  H. D. de Koning,et al.  Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis , 2016, Cancer.

[14]  Klaus Jung,et al.  Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. , 2002, Clinical chemistry.